NeueHealth, Inc.
Description
NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.
About
CEO
Mr. George Lawrence Mikan III
Employees
1,252
Instrument type
Common Stock
Sector
Healthcare
Industry
Healthcare Plans
MIC code
XNYS
Address
9250 NW 36th St, Doral, FL 33178, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 7, 2024 | -3.10 | -3.92 | -0.82 | 26.45% |
| Aug 7, 2024 | -3.26 | -7.27 | -4.01 | 123.01% |
| May 8, 2024 | -5.30 | -7.54 | -2.24 | 42.26% |
| Mar 6, 2024 | -4.16 | 20.05 | 24.21 | -581.97% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 2 |
| Average estimate | — | -4.18 | — | -12.83 |
| Low estimate | — | -4.18 | — | -16.66 |
| High estimate | — | -4.18 | — | -9.01 |
| Last year EPS | — | -5.40 | — | -15.20 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-118.790%
Next qtr. (Mar 2025)
22.570%
Current year
-28.340%
Next year (Dec 2025)
15.540%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.16B | 751.16M | 1.51B | 514.89M | 280.67M |
| Cost of revenue | 996.58M | 662.97M | 1.29B | 451.92M | 224.39M |
| Gross profit | 164.22M | 88.19M | 218.88M | 62.97M | 56.29M |
| Operating expense | |||||
| Research & development | — | — | — | 19.43M | 7.24M |
| Selling general and admin | 259.16M | 315.11M | 465.48M | 203.53M | 153.93M |
| Other operating expenses | 27.98M | 39.33M | 56.18M | 20.35M | 11.08M |
| Operating income | -141.21M | -296.96M | -343.63M | -170.38M | -125.34M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 38.20M | 12.82M | 7.23M | — | — |
| Other income expense | -449.75M | -71.80M | 1.23M | 8.47M | 8.35M |
| Pretax income | -629.17M | -381.58M | -349.63M | -170.38M | -125.34M |
| Tax provision | -1.43M | 3.66M | -26.52M | -9.16M | — |
| Net income | -1.27B | -1.36B | -1.18B | -248.44M | -125.34M |
| Basic EPS | -150.94 | -190.40 | -241.60 | -32.30 | -16.29 |
| Diluted EPS | -150.94 | -190.40 | -241.60 | -32.30 | -16.29 |
| Basic average shares | 7.95M | 7.85M | 4.90M | 7.69M | 7.69M |
| Diluted average shares | 7.95M | 7.85M | 4.90M | 7.69M | 7.69M |
| EBITDA | -117.05M | -246.38M | -306.92M | -162.09M | -124.20M |
| Net income from continuing op. | -1.27B | -1.36B | -1.18B | -248.44M | -125.34M |
| Minority interests | 114.35M | -95.66M | -6.50M | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.23B | 4.67B | 3.60B | 1.81B | 820.36M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 87.30M | 217.01M | 289.28M | 488.37M | 522.91M |
| Other short term investments | 6.27M | 869,000 | 144.48M | 499.93M | 107.68M |
| Accounts receivable | 154.96M | 118.76M | 98.88M | 60.52M | 787,000 |
| Other receivables | 115.88M | 99.18M | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 291.71M | 130.99M | 17.22M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | 822.57M | 3.19B | 1.03B | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 17.83M | 46.54M | 100.21M | 130.99M | 17.22M |
| Non current assets | |||||
| Properties | 1.11M | 1.03M | 1.09M | 705,000 | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 14.22M | 20.96M | 38.80M | 13.20M | — |
| Construction in progress | — | — | — | — | — |
| Leases | 7.37M | 9.18M | 7.14M | 3.60M | — |
| Accumulated depreciation | -8.19M | -9.88M | -8.68M | -5.25M | — |
| Goodwill | 93.24M | 907.72M | 2.00B | 678.28M | 58.96M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 93.24M | 104.95M | 337.00M | 152.21M | 18.71M |
| Investments and advances | — | 5.40M | 18.61M | 175.18M | 115.35M |
| Other non current assets | 28.82M | 561.38M | 713.20M | 28.31M | 14.34M |
| Total liabilities | 1.48B | 3.73B | 2.32B | 2.27B | 1.08B |
| Current liabilities | |||||
| Accounts payable | 169.74M | 134.74M | 321.08M | 307.03M | 77.95M |
| Accrued expenses | — | — | — | — | — |
| Short term debt | 303.95M | 303.95M | 155.00M | — | — |
| Deferred revenue | — | 242,000 | 2.59M | 34.63M | 16.01M |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | 793.59M | 3.25B | 1.80B | 35.85M | 14.14M |
| Non current liabilities | |||||
| Long term debt | 66.40M | — | — | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 22.44M | 32.21M | 41.26M | 28.58M | 16.84M |
| Shareholders equity | |||||
| Common stock | 1,000 | 1,000 | 63,000 | 14,000 | 14,000 |
| Retained earnings | -4.31B | -3.16B | -1.70B | -515.99M | -267.55M |
| Other shareholders equity | -122,000 | -4.43M | -3.34M | 2.43M | 982,000 |
| Total shareholders equity | -254.62M | 939.69M | 1.27B | -464.07M | -263.37M |
| Additional paid in capital | 3.06B | 2.97B | 2.86B | 9.88M | 3.18M |
| Treasury stock | 12.00M | 12.00M | 12.00M | — | — |
| Minority interest | 88.91M | 219.76M | 128.41M | 39.60M | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -1.27B | -1.36B | -1.18B | -248.44M | -125.34M | -62.64M |
| Depreciation | 24.17M | 50.58M | 35.48M | 8.29M | 1.13M | 1.03M |
| Deferred Taxes | -3.06M | 2.03M | -25.65M | — | — | — |
| Stock-Based Compensation | 83.69M | 109.71M | 68.42M | 5.45M | 1.86M | 257,000 |
| Other Non-Cash Items | 1.86M | 10.63M | 20.25M | 2.67M | -1.33M | 89,000 |
| Accounts Receivable | -24.45M | -70.39M | -32.94M | 24.63M | -201,000 | -568,000 |
| Accounts Payable | -149.33M | 2.70M | 192.61M | -3.96M | 25.55M | 17.95M |
| Other Assets & Liabilities | 180.83M | -64.59M | -128.56M | -25.44M | -1.85M | -282,000 |
| Operating Cash Flow | -1.15B | -1.32B | -1.06B | -236.80M | -100.17M | -44.17M |
| Investing Activities | ||||||
| Capital Expenditures | -2.90M | -27.45M | -30.41M | -6.47M | -793,000 | -694,000 |
| Net Intangibles | — | — | — | — | — | — |
| Net Acquisitions | -682,000 | -310,000 | -431.79M | -230.33M | -31.86M | — |
| Purchase of Investments | -837.07M | -1.46B | -1.02B | -916.82M | -300.33M | -166.82M |
| Sale of Investments | 1.96B | 1.06B | 926.90M | 463.89M | 238.33M | 160.57M |
| Investing Cash Flow | 1.12B | -429.72M | -552.89M | -689.74M | -94.64M | -6.94M |
| Financing Activities | ||||||
| Long-Term Debt Issuance | 66.40M | — | — | — | — | — |
| Long-Term Debt Payments | — | -155.00M | -200.00M | — | — | — |
| Other Financing Charges | -16.49M | -4.31M | -10.08M | — | — | — |
| Financing Cash Flow | 49.91M | 911.37M | 843.64M | 712.44M | 424.06M | 203.06M |
| Other Cash Details | ||||||
| End Cash Position | 375.28M | 1.93B | 1.06B | 488.37M | 522.91M | 201.70M |
| Income Tax Paid | — | — | — | — | — | — |
| Interest Paid | 36.17M | 10.30M | 4.59M | — | — | — |
| Free Cash Flow | -2.73B | 207.02M | 51.65M | -63.71M | -9.00M | -27.73M |
Error: Invalid format in Holders JSON file.
Article
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeueHealth, Inc. (NEUE) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE) and New Enterprise Associates ("NEA") (: ). Investors who purchased NeueHealth and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NEUE.
Feb 9, 2025
Article
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeueHealth, Inc. (NEUE) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE) and New Enterprise Associates ("NEA") (: ). Investors who purchased NeueHealth and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NEUE.
Feb 5, 2025
Article
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeueHealth, Inc. (NEUE) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE) and New Enterprise Associates ("NEA") (: ). Investors who purchased NeueHealth and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NEUE.
Feb 2, 2025
